Key Points
Question Does early tocilizumab administration prevent clinical worsening in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia?

Findings In this randomized clinical trial of 126 patients with a partial pressure of arterial oxygen to fraction of inspired oxygen (Pao2/Fio2) ratio between 200 and 300 mm Hg at enrollment, the rate of the primary clinical end point (clinical worsening) was not significantly different between the control group a...

The coronavirus disease 2019 (COVID-19) pandemic has caused significant disruptions to education for surgical residents across the country. Residents have experienced reduced operative exposure, decreased time caring for hospitalized patients, and altered rotation schedules. A number of studies have been published since the start of the COVID-19 pandemic regarding the effect of the crisis on residents and resident education across fields including internal medicine, emergency medicine, o...

AbstractThe coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still wreaking havoc in many parts of the world and poses a great burden to healthcare systems worldwide. Mitigation and suppression strategies have been implemented globally but the disease has proven to be difficult to contain. Initially many elective gastrointestinal (GI) endoscopies were cancelled to reduce the risk of infection and conserve personal protective e...

Abstract
The individual infectiousness of coronavirus disease 2019 (COVID-19), quantified by the number of secondary cases of a typical index case, is conventionally modelled by a negative-binomial (NB) distribution. Based on patient data of 9120 confirmed cases in China, we calculated the variation of the individual infectiousness, i.e., the dispersion parameter k of the NB distribution, at 0.70 (95% confidence interval: 0.59, 0.98). This suggests that the dispersion in the indi...

Abstract
This study used a national administrative database to estimate perioperative SARS‐CoV‐2 infection risk, and associated mortality, relative to nosocomial transmission rates. The impact of nosocomial transmission was greatest after major emergency surgery, whereas laparoscopic surgery may be protective owing to reduced duration of hospital stay. Procedure‐specific risk estimates are provided to facilitate surgical decision‐making and informed consent.

      &nb...

Abstract
This online structured survey has demonstrated the global impact of the COVID‐19 pandemic on vascular services. The majority of centres have documented marked reductions in operating and services provided to vascular patients. In the months during recovery from the resource restrictions imposed during the pandemic peaks, there will be a significant vascular disease burden awaiting surgeons.







For reading full text click the link

Abstract
Interindividual clinical variability in the course of SARS-CoV-2 infection is immense. We report that at least 101 of 987 patients with life-threatening COVID-19 pneumonia had neutralizing IgG auto-Abs against IFN-ω (13 patients), the 13 types of IFN-α (36), or both (52), at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These au...

People infected with both flu and SARS-CoV-2 are more than twice as likely to die as someone with the new coronavirus alone, emerging evidence from England has shown.

An analysis by Public Health England (PHE) of cases from January to April 2020 also found that people with the two viruses were more at risk of severe illness. Most cases of coinfection were in older people, and more than half of them died.

The data, published as a preprint on medRxiv,1 were released ...

COVID-19 has a spectrum of potential heart manifestations with diverse mechanisms
The family of seven known human coronaviruses are known for their impact on the respiratory tract, not the heart. However, the most recent coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has marked tropism for the heart and can lead to myocarditis (inflammation of the heart), necrosis of its cells, mimicking of a heart attack, arrhythmias, and acute or protracted heart failure (musc...

Abstract
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last vis...

Editor

The pandemic resulting from the transmission of the SARS‐CoV‐2 to the human population has stressed every health care system in the world. The impact on the provision of surgical services has been profound and one of the first and ubiquitous responses was to cease all non‐essential surgical operating. HPB centres internationally have reported a reduction in the number of surgical resections and the adoption of non‐surgical management of pathologies that traditionally were tr...

Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we report a humanized monoclonal antibody, H014, that efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nanomolar concentrations by engaging the spike (S) receptor binding domain (RBD). H0...